HTGF et al. inject €4.3m into Algiax Pharmaceuticals

Algiax will use the capital to further develop its products and gain approval for the clinical testing stage of its solutions.

Company
Founded in 2011, Algiax develops drugs addressing central nervous system (CNS) illnesses and dysfunctions, with a focus on neuropathic pain. The company is headquartered in Erkrath.

People
Dr Martin Pfister led the deal for HTGF. KfW was represented by Dr Detlev Riesner. Dr Jürgen Schumacher is co-founder and managing director of Algiax.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Now researching
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds